The Phase 2 trial is designed to investigate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies.
In the trial, three patients demonstrated partial response and 15 patients maintained stable disease states.
The majority of the responses were sustained for greater than two months.
S*BIO CEO Jan-Anders Karlsson said the development of SB1518 in a second indication is a significant milestone in the clinical advancement of our lead JAK2 inhibitor.
"This trial closely follows our recent announcement of data from Phase 1/2 studies for SB1518 indicating its clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis and enlarged spleens," Karlsson said.